2025-07-20 - Analysis Report
Okay, here's the analysis of TG Therapeutics Inc. (TGTX), presented in a format suitable for a report.

**Report: TG Therapeutics Inc. (TGTX) Analysis**

**Company Overview:** TG Therapeutics Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

**1. Performance Analysis**

*   **Cumulative Return:**
    *   TGTX: 68.37%
    *   S&P 500 (VOO): 96.72%
    *   Difference: -28.35%
    *   Relative Spread: 16.1

**Analysis:** TGTX has underperformed the S&P 500 by 28.35% since the start date of data. Considering the range of historical spreads between TGTX and the S&P 500, the current spread of -28.35% is within the lower portion of its historical range, indicating TGTX's performance relative to the S&P 500 is not exceptionally poor historically, but still underperforming.

*   **Alpha, Beta Analysis:**

    | Year       | CAGR   | MDD   | Alpha    | Beta   | Cap(B) |
    | :----------- | :----- | :----- | :------- | :----- | :----- |
    | 2015-2017  | -6.0%  | 56.5% | -35.0%  | -0.1 | 1.3 |
    | 2016-2018  | -8.0%  | 58.6% | -26.0%  | 0.0   | 0.7 |
    | 2017-2019  | 74.0%  | 58.6% | 44.0%  | 0.0   | 1.8 |
    | 2018-2020  | 402.0% | 58.6% | 382.0% | -0.4 | 8.3 |
    | 2019-2021  | 125.0% | 63.5% | 76.0%  | -0.5 | 3.0 |
    | 2020-2022  | -76.0% | 70.4% | -78.0%  | -0.6 | 1.9 |
    | 2021-2023  | -350.0% | 70.4% | -368.0% | -0.8 | 2.7 |
    | 2022-2024  | 71.0%  | 73.1% | 45.0%  | -0.9 | 4.8 |
    | 2023-2025  | 75.0%  | 73.1% | 27.0%  | 0.4 | 6.0 |

**Analysis:**
*   **CAGR:** The Compound Annual Growth Rate (CAGR) shows significant fluctuations, indicating periods of high growth and substantial losses.
*   **MDD:** The Maximum Drawdown (MDD) is consistently high, reflecting the stock's volatility and potential for significant losses from peak to trough.
*   **Alpha:** Alpha values are highly variable, with some periods showing significant outperformance (positive Alpha) and others showing substantial underperformance (negative Alpha) relative to the benchmark.
*   **Beta:** Beta values range from -0.9 to 0.4, suggesting the stock's price is negatively correlated with the market. The Beta of 0.4 from 2023 to 2025 indicates lower volatility compared to the market.
*   **Cap(B):** The market capitalization ranges from $0.7B to $8.3B, indicating variations in the company's size and value over time.

**2. Recent Stock Price Trends**

*   **Current Price:** 37.91
*   **Previous Close:** 39.19
*   **Change:** -3.27 (-3.27%)
*   **5-day Moving Average:** 38.564
*   **20-day Moving Average:** 37.1802
*   **60-day Moving Average:** 37.1586

**Analysis:** The stock price decreased significantly, dropping by 3.27%. The 5-day moving average is above the 20-day and 60-day moving averages, suggesting recent upward momentum, but the recent price drop could signal a trend reversal.

**3. Technical Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.3399 (Low Risk)
*   **RSI:** 54.877 (Neutral)
*   **PPO:** 0.5544 (Positive)
*   **Hybrid Signal:** Buy 90% of cash (5 shares - Safe - MRI:0.33)
*   **Recent (20-day) Relative Spread Change:** +0.5 (Short-term Increase)
*   **Expected Return:** -242.0% (Long-term, vs. S&P 500)

**Analysis:** The MRI indicates low market risk. The RSI is neutral, suggesting the stock is neither overbought nor oversold. The PPO is positive, suggesting the short-term moving average is above the long-term moving average, indicating potential upward momentum. However, the significantly negative expected return suggests that, based on current models, long-term returns are expected to substantially underperform the S&P 500. The recent price drop of -3.27% amplifies short-term volatility concerns. The hybrid signal suggests a moderate buy recommendation.

**4. Recent News & Significant Events**

*   **[2025-07-20]:** TG Therapeutics Inc (TGTX) has recently made headlines due to major business developments, regulatory changes, or market events.
*   **[2025-07-19]:** Analysts are discussing TG Therapeutics Inc's (TGTX) recent performance and its outlook in the context of industry trends and global economic factors.
*   **[2025-07-17]:** TG Therapeutics Inc (TGTX)'s stock has shown notable volatility, influenced by recent news, earnings reports, or executive actions.
*   **[2025-07-16]:** Market experts highlight both risks and opportunities for TG Therapeutics Inc (TGTX), advising investors to monitor recent news and company announcements.

**Analysis:** The recent news indicates that TGTX is experiencing significant activity that is affecting its stock performance. These factors could be driving the recent volatility.

**5. Recent Earnings Analysis**

| 날짜       | EPS    | 매출      |
| :--------- | :----- | :-------- |
| 2025-05-09 | 0.03   | 0.12 B$  |
| 2024-11-07 | 0.03   | 0.08 B$  |
| 2024-08-09 | 0.05   | 0.07 B$  |
| 2024-05-06 | -0.07  | 0.06 B$  |
| 2025-05-09 | -0.07  | 0.06 B$  |

**Analysis:**
*   **EPS:** The Earnings Per Share (EPS) shows variability. The most recent EPS is 0.03, which indicates profitability.
*   **Revenue:** Revenue has generally been increasing, with the latest quarter showing $0.12 billion, which is the highest in the reported period.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue  | Profit Margin |
| :--------- | :------- | :------------ |
| 2025-03-31 | \$0.12B  | 87.14%        |
| 2024-12-31 | \$0.11B  | 85.77%        |
| 2024-09-30 | \$0.08B  | 88.86%        |
| 2024-06-30 | \$0.07B  | 88.70%        |
| 2024-03-31 | \$0.06B  | 91.43%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE     |
| :--------- | :------- | :------ |
| 2025-03-31 | \$0.24B  | 2.13%   |
| 2024-12-31 | \$0.22B  | 10.49%  |
| 2024-09-30 | \$0.19B  | 2.02%   |
| 2024-06-30 | \$0.18B  | 3.87%   |
| 2024-03-31 | \$0.16B  | -6.69%  |

**Analysis:**
*   **Revenue:** Revenue has been increasing steadily, reflecting potential growth in the company's operations.
*   **Profit Margin:** The profit margins are consistently high, indicating efficient management of costs relative to revenue.
*   **Equity:** Equity has been growing, indicating an increase in the net assets of the company.
*   **ROE:** The Return on Equity (ROE) shows variability. The latest ROE is 2.13%.

**7. Overall Analysis**

TG Therapeutics Inc. presents a mixed picture.

*   **Strengths:** The company demonstrates strong revenue growth, high profit margins, and a positive earnings trend. The recent positive news suggests active developments.
*   **Weaknesses:** The company has underperformed the S&P 500, exhibits high historical volatility, and shows a significantly negative expected return.
*   **Considerations:** Recent news and market activity appear to be influencing the stock's volatility.

**Recommendation:**

Based on the current analysis, a cautious approach is recommended. The company shows promise in revenue growth and profitability, but potential investors should be wary of the high volatility and underperformance relative to the S&P 500. Continuous monitoring of company news and financial reports is crucial.
